Search Results 951-960 of 15326 for alt

1. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS - Mayo Clinic

   - Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) < 3.0 x ULN. - Ejection fraction measured by echocardiogram (ECHO) or multi gated ...

2. Ruxolitinib Prior to Transplant in Patients With Myelofibrosis - Mayo Clinic

   Adequate hepatic function - AST/ALT <2.5 x IULN, Total Bilirubin <1.5 x IULN; Adequate hematopoietic function - Platelet ≥50 x 109/l and ANC ≥1.0 x 109/l ...

3. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma - Mayo Clinic

   Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be ≤ 2.5*ULN. Estimated glomerular filtration rate (eGFR) ≥ 30 milliliters ...

4. LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma - Mayo Clinic

   AST/SGOT or ALT/SGPT > 2.5 x ULN, or > 5 x ULN if liver metastases are present. Additional exclusion criteria for the triple combinations: LGX818/MEK162 ...

5. A Study to Compare Tisagenlecleucel vs. Standard of Care in Adult Patients with Aggressive B-cell Non-Hodgkin Lymphoma - Mayo Clinic

   Alanine Transaminase (ALT) and Aspartate Transiminase (AST) ≤ 5 × ULN;; Total bilirubin ≤ 1.5 x ULN with the exception of patients with Gilbert syndrome ...

6. A Study to Assess the Effectiveness of Osimertinib Plus Savolitinib in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study) Following Prior Osimertinib - Mayo Clinic

   Participation eligibility · Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x the upper limit of normal (ULN) with total bilirubin ( ...

7. Bemarituzumab plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone - Mayo Clinic

   - Aspartate aminotransaminase (AST) and Alanine aminotransaminase (ALT) <3 x upper limit of normal (ULN) (or < 5 x ULN if liver involvement) - Total ...

8. Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer - Mayo Clinic

   AST(SGOT)/ALT(SGPT) ≤2.5 X institutional upper limit of normal; creatinine within normal institutional limits OR; creatinine clearance ≥60 mL/min/1.73 m2 ...

9. A Study to Assess the Effectiveness and Safety of Apremilast in Pediatric Patients (6 through 17 years old) with Moderate-to-Severe Plaque Psoriasis - Mayo Clinic

   ... (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 1.5 x ULN for age and gender. If initial test of ALT or AST is > 1.5 x ULN, one repeat test is allowed ...

10. A Phase Ⅲ Study Of Rilvegostomig In Combination With Fluoropyrimidine And Trastuzumab Deruxtecan As The First-line Treatment For HER2-positive Gastric Cancer - Mayo Clinic

    ALT is normal. Remain on anti-viral therapy, per institutional practice, during the study intervention and follow-up periods to ensure adequate viral ...